0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Cutaneous Embolization of Doxorubicin Drug-Eluting Beads FREE

Elizabeth Grieshaber, MD1; Thomas Nicotri, MD1; Rachel Reina, MD2; Katherine Rupley, BS3; Alun Wang, MD, PhD4
[+] Author Affiliations
1Department of Dermatology, Louisiana State University Health Sciences Center, New Orleans
2Baldone Reina Dermatology, Covington, Louisiana
3Louisiana State University Health Sciences Center, New Orleans
4Dermatopathology Section, Department of Pathology and Laboratory Medicine, Tulane University Health Sciences, Tulane University School of Medicine, New Orleans, Louisiana
JAMA Dermatol. 2014;150(10):1118-1120. doi:10.1001/jamadermatol.2014.305.
Text Size: A A A
Published online

Transarterial chemoembolization (TACE) with drug-eluting microspheres (DEMs) is emerging as the therapy of choice by many interventional oncologists and radiologists for unresectable liver tumors. Improvements in drug delivery systems have been made by modification of the embolic agents and the introduction of microcatheters, allowing for precise drug delivery to tumors. Currently, DEMs are being used as the drug delivery system for TACE.1 We report herein a case of cutaneous embolization of doxorubicin-impregnated DEMs after DEM TACE treatment for breast carcinoma metastasized to the liver.

REPORT OF A CASE

A woman in her 60s with a history of metastatic breast carcinoma presented with a painful pruritic eruption on her abdomen. One week earlier, she had undergone doxorubicin DEM TACE treatment for liver metastasis with doxorubicin DEM (100-300 µm/75 mg doxorubicin) (LC Beads; Biocompatibles UK Ltd). On physical examination, her right abdominal skin had tender reticulate erythematous nodules coalescing into plaques. Laboratory abnormalities were noted, including a white blood cell count of 17 700/μL and elevated transaminase levels (to convert white blood cells to ×109/L, multiply by 0.001). Punch biopsy histologic findings were consistent with a drug reaction characterized by a lymphocytic infiltrate with eosinophils in the reticular dermis.

At 1 week follow-up, her symptoms persisted with some skin ulceration (Figure, A), and an excisional biopsy was performed. Histologic analysis showed purple foreign material present within vessels and inflammation with focal necrosis within the adipose tissue (Figure, B). No fibrin clots or malignant cells were noted. An embolic process of the doxorubicin pellets in the vessels of the adipose tissue was suspected.

Place holder to copy figure label and caption
Figure.
Doxorubicin Drug Embolization

A, The clinical presentation shows cutaneous retiform erythematous papules, few with ulceration, after transarterial chemoembolization with drug-eluting microspheres (DEM). B, The histopathologic findings show a foreign material, thought to be a component of DEM, within a vessel of adipose tissue (hematoxylin-eosin, original magnification ×40). This finding was supported by x-ray analysis (not shown).

Graphic Jump Location

The excisional biopsy specimens and DEM were submitted for x-ray analysis. The element and atomic percentages were noted. The doxorubicin DEM showed carbon (65.77%), oxygen (27.91%), sulfur (1.88%), sodium (3.52%), and chloride (0.92%) elements . The skin specimen revealed carbon (76.2%), oxygen (20.14%), sodium (2.89%), and scant sulfur (0.77%) content. The sodium from the skin specimen likely corresponded to the sodium chloride within the microspheres. The finding of similar atomic percentages between the same elements in both samples supports the idea that the beadlike material visible in the skin and the DEM were from the same source. Our patient’s pruritus was treated with lidocaine cream; her skin lesions improved; and her laboratory findings returned to baseline.

DISCUSSION

The advantages of DEM TACE include delivery of higher doses of chemotherapy and prolonged tumor contact time while reducing the systemic toxic effects of chemotherapeutic agents.2 DEM TACE is being used for treatment of unresectable hepatocellular carcinoma, metastatic breast cancer, metastatic colon cancer, neuroendocrine tumors, cholangiocarcinoma, and metastatic melanoma, among others.2,3 The most common adverse effects after the procedure are nausea, vomiting, pain, and elevated transaminase levels.4

Embolic agents have improved dramatically with the development of microspheres. Embolization with microspheres alone is approved by the US Food and Drug Administration for hypervascular tumors and arteriovenous malformations. DEMs are being used for chemoembolization of malignant tumors. Microspheres are hydrophilic, and the size is precisely calibrated.5

There are 2 commercially available DEMs: DC/LC Beads (Biocompatibles UK Ltd) and HepaSphere (Biosphere Medical Inc).2,5 The negative charge on both of these microspheres allows positively charged drugs like doxorubicin or irinotecan to be loaded into the beads.5 Then, prior to injection of the doxorubicin DEM, an angiogram is performed to evaluate degree of hepatic tumor perfusion and extrahepatic perfusion.4 A microcatheter is then positioned for injection of the doxorubicin DEM, and the drug is delivered.2

The patient described herein represents a case of cutaneous embolization of DEM. We hypothesize that embolization into the subcutaneous fat occurred through the development of collateral vasculature in our patient. We suspect that this will become more common as smaller DEMs are being used for treating tumors.

ARTICLE INFORMATION

Corresponding Author: Thomas Nicotri, MD, Department of Dermatology, Louisiana State University Health Sciences Center, 1542 Tulane Ave, Ste 639, New Orleans, LA 70112 (tnicot@lsuhsc.edu).

Published Online: July 2, 2014. doi:10.1001/jamadermatol.2014.305.

Conflict of Interest Disclosures: None reported.

Previous Presentation: This case was presented at the 2012 Zola Cooper Meeting; November 10, 2012; New Orleans, Louisiana.

REFERENCES

Song  MJ, Chun  HJ, Song  S,  et al.  Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57(6):1244-1250.
PubMed   |  Link to Article
Jarząbek  M, Jargiełło  T, Wolski  A, Poluha  P, Szczerbo-Trojanowska  M.  Drug-eluting microspheres transarterial chemoembolization (DEM TACE) in patients with liver metastases. Pilot study. Pol J Radiol. 2011;76(3):26-32.
PubMed
Devaux  S, Du Thanh  A, Gallix  B, Girard  C, Dereure  O, Guillot  B.  Hepatic transarterial chemoembolization (HACE) with cisplatin in liver metastases from cutaneous melanoma: a prospective study of three patients. J Eur Acad Dermatol Venereol. 2013;27(2):e261-e262.
PubMed   |  Link to Article
Martin  RC, Robbins  K, Fagés  JF,  et al.  Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin. Breast Cancer Res Treat. 2012;132(2):753-763.
PubMed   |  Link to Article
Osuga  K, Maeda  N, Higashihara  H,  et al.  Current status of embolic agents for liver tumor embolization. Int J Clin Oncol. 2012;17(4):306-315.
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Figure.
Doxorubicin Drug Embolization

A, The clinical presentation shows cutaneous retiform erythematous papules, few with ulceration, after transarterial chemoembolization with drug-eluting microspheres (DEM). B, The histopathologic findings show a foreign material, thought to be a component of DEM, within a vessel of adipose tissue (hematoxylin-eosin, original magnification ×40). This finding was supported by x-ray analysis (not shown).

Graphic Jump Location

Tables

References

Song  MJ, Chun  HJ, Song  S,  et al.  Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57(6):1244-1250.
PubMed   |  Link to Article
Jarząbek  M, Jargiełło  T, Wolski  A, Poluha  P, Szczerbo-Trojanowska  M.  Drug-eluting microspheres transarterial chemoembolization (DEM TACE) in patients with liver metastases. Pilot study. Pol J Radiol. 2011;76(3):26-32.
PubMed
Devaux  S, Du Thanh  A, Gallix  B, Girard  C, Dereure  O, Guillot  B.  Hepatic transarterial chemoembolization (HACE) with cisplatin in liver metastases from cutaneous melanoma: a prospective study of three patients. J Eur Acad Dermatol Venereol. 2013;27(2):e261-e262.
PubMed   |  Link to Article
Martin  RC, Robbins  K, Fagés  JF,  et al.  Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin. Breast Cancer Res Treat. 2012;132(2):753-763.
PubMed   |  Link to Article
Osuga  K, Maeda  N, Higashihara  H,  et al.  Current status of embolic agents for liver tumor embolization. Int J Clin Oncol. 2012;17(4):306-315.
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

538 Views
0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
×